Working... Menu

To Evaluate the Efficacy and Safety of SCB01A in Subjects With r/m Squamous Cell Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03020823
Recruitment Status : Withdrawn (withdrawal by sponsor)
First Posted : January 13, 2017
Last Update Posted : February 17, 2017
Information provided by (Responsible Party):
SynCore Biotechnology Co., Ltd.

Brief Summary:
The aim of this study is to evaluate the efficacy and safety of i.v. infusion for 24-hour of SCB01A in subjects with squamous cell carcinoma of head and neck who have failed previous platinum based therapies.

Condition or disease Intervention/treatment Phase
Head and Neck Neoplasms Drug: SCB01A Phase 2

Detailed Description:

From pre-clinical pharmacology and phase I clinical study SCB01A has demonstrated promising anticancer action with a vascular disrupting activity that has the potential for treatment of various malignancies, particularly for patients with drug resistance. The drug has been studied in human subjects in a dose escalation phase I study and has shown to be safe for up to 2 cycles of 24 mg/m2 (each cycle consisting of one intravenous [i.v.] administration of SCB01A via a central line every 3 weeks). In the phase I study, partial response (PR) (shrinkage of tumor size to 50%) was observed in cycle 9 (3 mg/m2) of one subject with right buccal squamous cell carcinoma and 19/33 (58%) subjects had stable disease (SD) for more than 2 cycles.

Pre clinical study of SCB01A showed that the concentrations at which tubulin inhibition occurred were around 80 nM for 24-hour exposure or 200 nM for 6-hour exposure. However, pharmacokinetic (PK) results of phase I study showed that the average elimination half-life (t1/2) of a 3-hours i.v. infusion of SCB01A is approximately 2.5 hours and almost no SCB01A can be detected after 10 hours, indicating most subjects were treated in short API exposure time and may have been insufficient to achieve efficacy. Therefore, to extend the exposure duration above effective concentration in blood may increase the treatment efficacy.

The aim of this study is to evaluate the efficacy and safety of i.v. infusion for 24-hour of SCB01A in subjects with squamous cell carcinoma of head and neck who have failed previous platinum based therapies.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: An Open-Label, Phase II Study to Evaluate the Efficacy and Safety of SCB01A in Subjects With Recurrent or Metastatic Squamous Cell Head and Neck Cancer Who Have Failed Platinum-Based Treatment
Estimated Study Start Date : April 30, 2017
Estimated Primary Completion Date : April 2019
Estimated Study Completion Date : December 2019

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: SCB01A alone
intra-subject dose escalation starting from 12 mg/m2, then to18 mg/m2, and finally to 24 mg/m2 if no DLT
Drug: SCB01A
intra-subject dose escalation, 12, 18, 24 mg/m2, 24h-IV infusion (in the vein) on day 1 and 8 of each 21 day cycle. Number of Cycles: until progression or unacceptable toxicity develops.
Other Name: 6-Methoxy-3-(3',4',5'-trimethoxybenzoyl) indole

Primary Outcome Measures :
  1. Objective response rate (ORR) during treatment phase [ Time Frame: 2 years ]

Secondary Outcome Measures :
  1. Progression free survival (PFS) [ Time Frame: 2 years ]
  2. Overall survival (OS) [ Time Frame: 2 years ]
  3. Best overall tumor response [ Time Frame: 2 years ]
  4. Safety assessed by changes in Laboratory Data, AE/SAE Incidences, Physical Examination, Vital Sign, and Electrocardiogram [ Time Frame: 2 years ]
    • AE/SAE incidence
    • Physical examination result changes
    • Vital sign changes
    • Electrocardiogram (ECG) (including PR, QRS, QTc intervals) results

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   20 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Aged ≥20 years;
  2. Signed informed consent obtained prior to initiation of any study-specific procedures and treatment;
  3. Histological or cytological confirmed squamous cell carcinoma of head and neck, excluding nasopharyngeal carcinoma;
  4. Subjects with unresectable, unfeasible radiotherapy, recurrent or metastatic head and neck squamous cell carcinoma, after previous treatment with platinum agent;
  5. Subjects must have at least one measurable tumor lesion as defined by RECIST version 1.1 as assessed by the investigator (local radiological image assessment) or clinically evaluable disease. Physical and neurological examinations, and radiographic studies have to be performed within 28 days of Cycle 1 Day 1;
  6. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0-1;
  7. Life expectancy of 12 weeks or longer;
  8. Concurrent local therapy is not allowed, but concurrent palliative radiation therapy to non-measurable sites of disease such as painful bone metastasis is permitted;
  9. All eligible subjects of childbearing potential have to use effective contraception; that is, double barrier contraceptive methods;
  10. Documented progressive disease within past 6 months;
  11. Adequate bone marrow reserve, cardiac, renal and liver function:

    1. Absolute neutrophil count (ANC) > 1.5 x 109/L;
    2. White blood cell (WBC) > 3 x 109/L;
    3. Platelet count > 75 x 109/L;
    4. Hemoglobin > 9 g/dL ( > 5.6 mmol/l);
    5. Prothrombin time (PT)/international normalized ratio (INR) ≤1.5 x upper limit of normal (ULN);
    6. Creatinine clearance (Cockcroft & Gault formula) >50 mL/min;
    7. Alanine aminotransferase (ALT, SGPT) and aspartate aminotransferase (AST, SGOT) and Alkaline Phosphatase (ALP) < 3 x ULN; AST/ALT≦5 x ULN if liver metastasis;
    8. Serum albumin ≥ 3 g/dL;
    9. Total Bilirubin ≤ 1.5 x ULN;
    10. QTc <450 msec

Exclusion Criteria:

  1. Known primary CNS malignancy or CNS involvement (except for brain metastases that have been treated and are stable and subject is off steroids);
  2. Chemotherapy, radiation therapy, major surgery or investigational agents including immune or target therapies less than 4 weeks prior to study drug treatment;
  3. History of malignancy other than head and neck cancer with the exception of early stage non-melanoma skin cancer or carcinoma in situ of cervix;
  4. History of liver cirrhosis;
  5. Active hepatitis B or hepatitis C infection;
  6. Clinical significant pulmonary obstructive or clinical significant pulmonary restrictive diseases (grade >2);
  7. Clinically significant cardiac disease (NYHA class > 2);
  8. Other serious illness or medial conditions, such as active infection, unresolved bowel obstruction, or psychiatric disorders;
  9. Known HIV positivity;
  10. Pregnant or breast-feeding subjects, and men and women of child-bearing potential not using effective contraception while on study treatment;
  11. Known hypersensitivity to any component of SCB01A or excipients including Solutol®, alcohol, and PEG300;
  12. History of exposure to SCB01A or its analogues;
  13. History of active or significant neurological disorder or psychiatric disorder that would prohibit the understanding and giving of informed consent, or would interfere with the clinical and radiological evaluation of central nervous system during the trial;
  14. Peripheral neuropathy (≥ grade 2);
  15. Any other reason the investigator deems the subject to be unsuitable for the study.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03020823

Sponsors and Collaborators
SynCore Biotechnology Co., Ltd.
Layout table for investigator information
Principal Investigator: Her-Shyong Shiah, MD Taipei Medical University Hospital

Layout table for additonal information
Responsible Party: SynCore Biotechnology Co., Ltd. Identifier: NCT03020823     History of Changes
Other Study ID Numbers: SCB01A-22
First Posted: January 13, 2017    Key Record Dates
Last Update Posted: February 17, 2017
Last Verified: February 2017
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Keywords provided by SynCore Biotechnology Co., Ltd.:
squamous cell carcinoma of head and neck

Additional relevant MeSH terms:
Layout table for MeSH terms
Head and Neck Neoplasms
Neoplasms by Site